For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260216:nRSP2266Ta&default-theme=true
RNS Number : 2266T Plus500 Limited 16 February 2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR
FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION WHERE
TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH
JURISDICTION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND THE
INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR ACQUIRE
SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER
JURISDICTION.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE
INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO.
596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018, AS AMENDED BY THE MARKET ABUSE (AMENDMENT) (EU EXIT)
REGULATIONS 2019 (AS FURTHER AMENDED, VARIED OR SUBSTITUTED FROM TIME TO TIME
AS A MATTER OF UK LAW). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA THE
REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
16 February 2026
Plus500 Ltd.
("Plus500" or the "Company")
Proposed sale of 1,500,000 Existing Ordinary Shares in Plus500
David Zruia, CEO of Plus500, Elad Even-Chen, CFO of Plus500 and Nir Zats, CMO
of Plus500 (together the "Selling Shareholders"), announce their intention to
sell 1,500,000 existing ordinary shares (the "Shares") in the capital of
Plus500. The Shares represent approximately 2.14% of the Company's issued
share capital (excluding ordinary shares held in treasury).
The Shares will be sold on the secondary market to Goldman Sachs International
("Goldman Sachs") as principal, with the sale intermediated by Panmure Liberum
Limited ("Panmure Liberum"). Goldman Sachs may or may not onward sell the
Shares. Plus500 is not a party to the transaction and will not receive any
proceeds from the transaction.
The transaction is being undertaken by the Selling Shareholders for personal
financial and tax planning purposes. The Selling Shareholders have not sold
any shares in the Company since its IPO 13 years ago and remain highly
committed to the Company's long-term strategy, growth trajectory and value
creation for shareholders.
Further details are set out below:
Shares to be sold as part of the transaction Resultant 2026 shareholding assuming all Shares are sold(( 1 (#_ftn1) ))
Selling Shareholder # of Shares % of S/O # of Shares % of S/O
David Zruia 450,792 0.64% 1,298,468 1.85%
Elad Even-Chen 940,000 1.34% 1,298,468 1.85%
Nir Zats 109,208 0.16% 131,316 0.19%
Total 1,500,000 2.14% 2,728,252 3.89%
Assuming all the Shares are sold, after completion of the transaction, the
Selling Shareholders will continue to hold approximately 3.89%(1) of the
issued share capital of the Company. The Shares, in all respects, rank pari
passu with the Company's ordinary shares.
The Selling Shareholders have agreed with Panmure Liberum not to sell any
further ordinary shares they hold in the capital of the Company for a period
of 365 days after completion of the transaction, subject to waiver by Panmure
Liberum ("Lock-in Period").
For further details:
Panmure Liberum
Bidhi Bhoma, Dru Danford, David Watkins, Satbir Kler +44 20 3100 2000
1 (#_ftnref1) The total resultant shareholding assuming all 1,500,000 Shares
are sold is 2,728,252. This comprises 1,450,001 ordinary shares held as at the
date of this announcement and 1,278,251 ordinary shares expected to vest
during 2026 subject to performance conditions.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCFLFVRFFIRLIR
Copyright 2019 Regulatory News Service, all rights reserved